Literature DB >> 21357258

Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice.

Enayat Nikoopour1, Christian Sandrock, Katrina Huszarik, Olga Krougly, Edwin Lee-Chan, Emma L Masteller, Jeffrey A Bluestone, Bhagirath Singh.   

Abstract

Mechanistic and therapeutic insights in autoimmune diabetes would benefit from a more complete identification of relevant autoantigens. BDC2.5 TCR transgenic NOD mice express transgenes for TCR Vα1 and Vβ4 chains from the highly diabetogenic BDC2.5 CD4(+) T cell clone, which recognizes pancreatic β cell membrane Ags presented by NOD I-A(g7) MHC class II molecules. The antigenic epitope of BDC2.5 TCR is absent in β cells that do not express chromogranin A (ChgA) protein. However, characterization of the BDC2.5 epitope in ChgA has given inconclusive results. We have now identified a ChgA29-42 peptide within vasostatin-1, an N-terminal natural derivative of ChgA as the BDC2.5 TCR epitope. Having the necessary motif for binding to I-A(g7), it activates BDC2.5 T cells and induces an IFN-γ response. More importantly, adoptive transfer of naive BDC2.5 splenocytes activated with ChgA29-42 peptide transferred diabetes into NOD/SCID mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357258     DOI: 10.4049/jimmunol.1003617

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

2.  Novel autoantigens in type 1 diabetes.

Authors:  Shuhong Han; William Donelan; Hai Wang; Westley Reeves; Li-Jun Yang
Journal:  Am J Transl Res       Date:  2013-05-24       Impact factor: 4.060

Review 3.  Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.

Authors:  Suchitra Prasad; Dan Xu; Stephen D Miller
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 4.  The interplay of autoimmunity and insulin resistance in type 1 diabetes.

Authors:  Natalie J Nokoff; Marian Rewers; Melanie Cree Green
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

5.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

6.  Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.

Authors:  Suchitra Prasad; Tobias Neef; Dan Xu; Joseph R Podojil; Daniel R Getts; Lonnie D Shea; Stephen D Miller
Journal:  J Autoimmun       Date:  2017-12-16       Impact factor: 7.094

7.  IL-15 trans-presentation regulates homeostasis of CD4(+) T lymphocytes.

Authors:  Xi-Lin Chen; Diwakar Bobbala; Yuneivy Cepero Donates; Marian Mayhue; Subburaj Ilangumaran; Sheela Ramanathan
Journal:  Cell Mol Immunol       Date:  2014-03-24       Impact factor: 11.530

8.  Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg 17) cells in type 1 diabetes in non-obese diabetic mice.

Authors:  S M Bellemore; E Nikoopour; J A Schwartz; O Krougly; E Lee-Chan; B Singh
Journal:  Clin Exp Immunol       Date:  2015-09-22       Impact factor: 4.330

9.  Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.

Authors:  Lourdes Ramirez; Abdel Rahim A Hamad
Journal:  World J Diabetes       Date:  2013-08-15

10.  Detection of vasostatin-1-specific CD8(+) T cells in non-obese diabetic mice that contribute to diabetes pathogenesis.

Authors:  E Nikoopour; O Krougly; E Lee-Chan; S M Haeryfar; B Singh
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.